Theravance Biopharma, Inc. (TBPH)

NGM – Цена в реальном времени. Валюта: USD

16.93

+0.01 (0.09%)

Рынок открыт: Aug 12, 2026, 2:12 PM EDT

16.92

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

11.08.2026

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

10.08.2026

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restructuring and transaction costs) Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment 2 Quarter-end cash balance of $388 million and no debt DUBLIN, Aug. 10, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026. "During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

Видео

No Data

There is no data to display

Пресс-релизы

10.08.2026

Theravance Biopharma, Inc. (TBPH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Theravance Biopharma, Inc. (TBPH)

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Theravance Biopharma, Inc. (TBPH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Theravance Biopharma, Inc. (TBPH)

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Видео

No Data

Пресс-релизы

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update